These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29567282)

  • 1. Data monitoring committees and stopping trials-Giving participants a voice.
    Trachtman H; Caplan A
    Contemp Clin Trials; 2018 May; 68():146. PubMed ID: 29567282
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 1: Ethical considerations.
    Ball G; Piller LB; Silverman MH
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S2-4. PubMed ID: 21664987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current controversies in data monitoring for clinical trials.
    Pocock SJ
    Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data monitoring (and safety) committees--what are they and why do we need them? Primary Care Alliance for Clinical Trials (PACT) Network.
    Pirotta M; Chondros P;
    Aust Fam Physician; 2004 Nov; 33(11):950-1, 956. PubMed ID: 15584339
    [No Abstract]   [Full Text] [Related]  

  • 5. Continuous safety monitoring for randomized controlled clinical trials.
    Piller LB; Silverman MH; Ball G
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S1. PubMed ID: 21458597
    [No Abstract]   [Full Text] [Related]  

  • 6. Early stopping rules in oncology: considerations for clinicians.
    Mukherjee SD; Goffin JR; Taylor V; Anderson KK; Pond GR
    Eur J Cancer; 2011 Nov; 47(16):2381-6. PubMed ID: 21684153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The many moral responsibilities of independent data-monitoring committees.
    Braillon A
    Am J Bioeth; 2011 Mar; 11(3):16-7. PubMed ID: 21400378
    [No Abstract]   [Full Text] [Related]  

  • 8. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 9. Reporting on data monitoring committees in neonatal randomised controlled trials is inconsistent.
    Perrem LM; Gosling S; Ravikumar I; Khashan AS; Miletin J; Ryan CA; Dempsey E
    Acta Paediatr; 2017 Jan; 106(1):30-33. PubMed ID: 27637413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.
    Wells RJ; Gartside PS; McHenry CL
    IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010
    [No Abstract]   [Full Text] [Related]  

  • 11. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discussion of paper by Korn and Freidlin.
    Wittes J
    Am J Bioeth; 2011 Mar; 11(3):13-4. PubMed ID: 21400376
    [No Abstract]   [Full Text] [Related]  

  • 13. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.
    Wittes J; Barrett-Connor E; Braunwald E; Chesney M; Cohen HJ; Demets D; Dunn L; Dwyer J; Heaney RP; Vogel V; Walters L; Yusuf S
    Clin Trials; 2007; 4(3):218-34. PubMed ID: 17715247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dilemma of data-safety monitoring: provision of significant new data to research participants.
    Peppercorn J; Buss WG; Fost N; Godley PA
    Lancet; 2008 Feb; 371(9611):527-9. PubMed ID: 18262043
    [No Abstract]   [Full Text] [Related]  

  • 15. Early stopping of a randomised trial for efficacy: a medical, ethical and regulatory challenge.
    Darmon A; Ducrocq G
    Heart; 2021 Jul; 107(14):1109-1110. PubMed ID: 34021036
    [No Abstract]   [Full Text] [Related]  

  • 16. The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
    Anderson JR; Krailo M
    Am J Bioeth; 2011 Mar; 11(3):18-9. PubMed ID: 21400379
    [No Abstract]   [Full Text] [Related]  

  • 17. University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session).
    Dickersin K; Dixon D; Ferris F; Goldberg J; Kimmel S; Lachin J
    Clin Trials; 2018 Aug; 15(4):366-385. PubMed ID: 30021497
    [No Abstract]   [Full Text] [Related]  

  • 18. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data monitoring committees for clinical trials evaluating treatments of COVID-19.
    Mütze T; Friede T
    Contemp Clin Trials; 2020 Nov; 98():106154. PubMed ID: 32961361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.